{"entity":{"id":"nct07374419","kind":"trial","name":"Atamparib in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of atamparib escalation levels in non-small-cell lung cancer, run by Nerviano Medical Sciences (Shanghai) Ltd., now recruiting.","summary":"Atamparib in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07374419 by Nerviano Medical Sciences (Shanghai) Ltd., with 178 participants planned, started 2026-03-18 and due to reach its primary completion in 2028-07-31. Interventions recorded: atamparib escalation levels and atamparib RP2D.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07374419","url":"https://clinicaltrials.gov/study/NCT07374419"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07374419","phase":"1/2","setting":"A Phase Ib/II Study of Atamparib in Patients With Advanced Solid Tumors","sponsor":"Nerviano Medical Sciences (Shanghai) Ltd.","enrolled":178,"outcomes":[]},"route":"/trials/nct07374419/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}